Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Current guidelines recommend potent P2Y12 inhibitors over clopidogrel for acute coronary syndrome (ACS) to reduce ischemic events.
• However, potent P2Y12 inhibitors are associated with an increased risk of bleeding.
• A guided selection strategy may optimize the balance between efficacy and safety.

Purpose of the Study:

• To evaluate the comparative safety and efficacy of guided versus routine selection of potent P2Y12 inhibiting therapy in ACS patients.
• To determine if a guided approach can mitigate the increased bleeding risk associated with potent P2Y12 inhibitors.

Main Methods:

• Network meta-analysis of randomized controlled trials (RCTs) comparing oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) in ACS patients.
• Inclusion of RCTs with guided (platelet function or genetic testing) versus standard P2Y12 inhibitor selection.
• Estimation of incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for efficacy (major adverse cardiovascular events - MACE) and safety (all bleeding) endpoints.

Main Results:

• A guided approach was the only strategy associated with reduced MACE (IRR: 0.80, 95% CI: 0.65-0.98) without a significant increase in bleeding.
• Guided approach and prasugrel reduced myocardial infarction; guided approach, prasugrel, and ticagrelor reduced stent thrombosis.
• Ticagrelor reduced mortality, while prasugrel and ticagrelor were associated with increased bleeding.

Conclusions:

• Guided selection of P2Y12 inhibiting therapy in ACS patients demonstrates a superior safety and efficacy profile compared to routine selection.
• These findings advocate for wider implementation of guided P2Y12 inhibitor selection in ACS management.